-
-
-
-
-
-
News
-
-
Contact UsThe company focuses on the research, development, production, and sales of chemical raw materials and their formulations. All products have passed national GMP certification, and core products have successively passed official pharmaceutical regulatory certifications from multiple countries, including the EU EDQM, US FDA, Japanese PMDA, and South Korean MFDS. Following its successful listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a phase of rapid development driven by both digital intelligence and capital, with its business spanning dozens of countries and regions worldwide.
Keyuan News
20
2026-05
To thoroughly implement the latest requirements of the Criminal Law Amendment (No. 12), effectively strengthen all employees’ awareness of integrity and compliance, prevent and mitigate internal risks of official misconduct, and safeguard the company’s high-quality development, on May 20, Keyuan Group organized a company-wide training session on corruption prevention and compliance. Led by the Human Resources Center and the Audit Center, the event adopted a hybrid online–offline format to ensure full coverage, mandatory participation, and comprehensive learning for all employees.
2026-05-20
17
2026-05
On May 16–17, Wu Xiaobo, known as “China’s foremost financial writer” and a renowned entrepreneur, led a delegation to visit and inspect Keyuan Pharmaceutical (stock code: 301281.SZ). The group focused on the company’s achievements in integrating intelligent manufacturing with digital AI technologies in the pharmaceutical sector, engaged in in-depth discussions with its core management team, and expressed strong recognition of its practical approach to driving industrial upgrading through digital and intelligent transformation. Gao Yuankun, Chairman and President of Linuo Group, along with Li Hongfu, Chairman of Keyuan Pharmaceutical, and Wei Zhiguo, President of the company, accompanied the delegation during the visit.
2026-05-17
13
2026-05
On May 13, the 92nd National Pharmaceutical Fair and the 94th China International API, Intermediates, Packaging, and Equipment Fair (API China) opened simultaneously at the Shanghai National Exhibition and Convention Center. As an innovative, publicly listed company in China’s chemical pharmaceutical sector, Shandong Keyuan Pharmaceutical Co., Ltd. (301281.SZ), together with its wholly owned subsidiary Shandong Linuo Pharmaceutical Co., Ltd., made a high‑profile appearance, showcasing synergistic raw material–formulation integration, end-to-end product displays, and brand resonance. The company highlighted its robust capabilities in innovative R&D, digital and intelligent manufacturing, green production, global supply chains, and clinical translation, while engaging domestic and international partners to explore new industry trends, expand avenues for collaboration, and build a new ecosystem for the pharmaceutical and healthcare sectors.
2026-05-13
07
2026-05
Good News! A Subsidiary of Keyuan Pharmaceutical Has Been Selected!
Recently, Keyuan Pharmaceutical has been celebrating one success after another! Its solid dosage-form workshop has just been awarded the First Prize in the 2025 “Making Contributions to the Spring City” Innovation and Excellence Labor Competition, while its injectable digital-intelligent factory has once again delivered exciting news: thanks to its cutting-edge smart manufacturing capabilities, a comprehensive digital-intelligent system, and remarkable achievements in implementation, it has been successfully recognized as a Basic-Level Smart Factory in Jinan for 2026.
2026-05-07
27
2026-04
On April 27, Hou Zhanfu, Secretary of the Yinan County Party Committee, and Ren Lijun, a member of the County Government Party Leadership Group and Deputy County Magistrate, led a delegation comprising heads of the County Health Commission, the County Bureau of Industry and Information Technology, the County Finance and Investment Group, and other relevant departments on a field visit to Keyuan Pharmaceutical and Linuo Pharmaceutical to assess the companies’ development status and discuss ways to deepen government–enterprise cooperation and promote high-quality development of the pharmaceutical and health industries.
2026-04-27
27
2026-04
From April 24 to 27, the themed event “Tracing the Footsteps of a Mountain, a River, and a Sage; Exploring the Origins of Gold, an Award, and a Renowned Hall” was successfully held in Jinan. This event not only marked the official kickoff of the 2026 work conference of the Retail Pharmacy Branch and the Independent Pharmacy Branch of the China Association for Medical Supplies, but also formally inaugurated the “Climbing Mount Tai, Paying Respects at the Confucius Temple, Embarking on a New Journey—Hongjitang Pharmaceutical & Dengsheng Pharmaceutical’s Traditional Chinese Culture Tour: Joint Exploration of Non-Pharmaceutical Revenue Growth” series of activities.
2026-04-27
23
2026-04
From April 21 to 23, CPHI Japan 2026 was grandly held in Tokyo, Japan. Shandong Keyuan Pharmaceutical Co.,Ltd. (stock code: 301281.SZ) showcased its products in key therapeutic areas such as antidiabetic, cardiovascular, and anesthetic drugs at this exhibition, comprehensively demonstrating the company’s robust R&D and manufacturing capabilities as well as its internationally recognized achievements in the field of chemical APIs, while actively connecting with global pharmaceutical industry resources.
2026-04-23
21
2026-04
On April 21, Shandong Lino Pharmaceutical Co., Ltd., a wholly owned subsidiary of Shandong Keyuan Pharmaceutical Co.,Ltd. (stock code: 301281.SZ), and Hubei General Pharmaceutical Co., Ltd. held a grand strategic cooperation signing ceremony. The two parties will join forces and complement each other’s strengths to deepen comprehensive cooperation in areas such as product distribution, industrial chain synergy, and medical terminal coverage, thereby focusing on serving the “Healthy China” strategy and jointly building a new pattern of high-quality development in the pharmaceutical industry.
2026-04-21
14
2026-04
On April 14, in-cosmetics Global 2026—the premier European trade show for cosmetic ingredients—kicked off with great fanfare at the Paris Expo Porte de Versailles in France. As a leading player in the pharmaceutical-grade active ingredient segment, Keyuan Pharmaceutical (stock code: 301281.SZ) showcased its full portfolio of high-purity, pharmaceutical-grade cosmetic ingredients, bioactive functional ingredients, and customized solutions, thereby forging a bridge for collaboration between China’s pharmaceutical industry and the global beauty market.
2026-04-14
08
2026-04
With the vigorous spring breeze ushering in a new journey, we are uniting our hearts and pooling our strengths to tackle the toughest challenges once again. On April 8, Keyuan Group (Keyuan Pharmaceutical, stock code 301281.SZ; Linuo Pharmaceutical) solemnly convened the “First-Quarter Strong Start and Second-Quarter Mobilization Conference.” Chairman Li Hongfu, President Wei Zhiguo, other members of the management team, heads of all business units and regional divisions within the Marketing Center, as well as representatives from relevant functional departments, gathered to conduct a comprehensive review of the first-quarter marketing performance, outline the key tasks for the second quarter and the full year, and sound the rallying call for an all-out sprint toward achieving the year’s targets.
2026-04-08
Address: No. 26, Keyuan Street, Shanghe County, Jinan City, Shandong Province
Free Service Hotline